Q4 2025 earnings call recap: evorpacept/CD47 biomarker data, ASPEN-09 expansion, ALX2004 updates, and $150M raise—read now.
ALX Oncology pivots to targeting HER2-positive underperformance in the intent-to-treat gastric cancer population. See why ...
Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains ...
Elon Musk and other tech leaders explore building data centres in space to overcome terrestrial constraints, with launch ...
As AI scaling laws hit the data plateau, executives face a stark choice: hit the scaling wall or remain an innovator. This ...
Acadia plans re-examination after CHMP rejects Rett syndrome drug trofinetide in the EU, delays potential approval despite ...
Alexander's (ALX) came out with quarterly funds from operations (FFO) of $2.43 per share, missing the Zacks Consensus Estimate of $3.02 per share. This compares to FFO of $4.06 per share a year ago.
The Associated Press today announced that it will provide its U.S. elections results to Kalshi, the world’s largest prediction market. AP will provide ...
Here is how Teva Pharmaceutical Industries Ltd. (TEVA) and ALX Oncology Holdings Inc. (ALXO) have performed compared to their sector so far this year.
About ALX Oncology Holdings Inc. ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results